Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.

CPE-003 · synthetic case CKD-FX-015

ACE inhibitor monitoring rather than automatic cessation

Synthetic · no real patientReviewed acceptance scenarioKidney engine v1.2.0

Purpose: Support guideline-concordant medication stewardship

Inputs the engine received

Context

CKD confirmed: Yes
ACEi or ARB initiated or dose increased: Yes

Laboratory

Serum creatinine increase percent within 4 weeks: 18 %
Potassium: 4.8 mmol/L

What the engine reports

Priority

Adult-only pathway

DQ-001

CPE-003 is validated for adults only; route to the pediatric kidney pathway or provide age.

Detected clinical pattern

Excluded or Data Insufficient

Age is missing or outside the validated adult pathway.

Chronicity: Chronicity confirmed (≥3 months)

Clinical summary

Physician adjudication required.

Recommended next steps

For physician consideration. Urgent review always comes first.

1Monitor blood pressure, serum creatinine and potassium within 2–4 weeks after an ACEi/ARB start or dose increase.

Missing information

Age (required for eGFR and for the adult-only pathway).
UACR (required for the A category, risk assessment and a complete classification).

Why it matters

The result is placed in context so the physician can see what is established, what is provisional and what is missing.

Evidence and rule trace · 2 rules

DQ-001Adult-only validated pathway

Inputs: age missing

excluded_or_data_insufficient

MED-RASI-001RAS inhibitor post-initiation monitoring

Inputs: ACEi/ARB initiated or dose increased

Monitor BP, serum creatinine and potassium within 2–4 weeks

Evidence

R1 · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2024.
R3 · eGFR Equations for Adults: 2021 CKD-EPI creatinine and creatinine-cystatin C race-free equations. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / NIH, 2026.

Physician adjudication required. Clinical decision support for physician review. Criteria-based status is not a probability. Findings require physician adjudication and correlation with the complete clinical context. Validation-only release: not for production clinical use.

Change the values

The same engine, starting from this case. Change any value and watch the pattern and the rule trace react.

Load a synthetic case

Live eGFR and CGA map

eGFR (mL/min/1.73 m²)

—

enter a creatinine

GFR \ ALB	A1<30	A230–300	A3>300
G1≥90
G260–89
G3a45–59
G3b30–44
G415–29
G5<15

No cell is shown until there are data. Colors follow the KDIGO risk heat map: green low, yellow moderately increased, orange high, red very high.

Kidney functionAdd a prior result with dates to test chronicity

Age(years)

Sex for the equation

FemaleMale

Serum creatinine (current)(mg/dL)

Collection date

Serum creatinine (prior)(mg/dL)

Prior collection date

Cystatin C (optional)(mg/L)

Switches the engine to the combined eGFRcr-cys equation.

Albuminuria

UACR (current)(mg/g)

Collection date

UACR (prior)(mg/g)

Prior collection date

Specimen type

UPCR (optional)(mg/g)

Chemistry

Potassium(mmol/L)

Specimen hemolysis

Bicarbonate(mmol/L)

Hemoglobin(g/dL)

Creatinine rise within 4 weeks of ACEi/ARB(%)

Kidney findings and red flags

Context

Transient albuminuria confounders

Creatinine may be unreliable

Complications (persistent)

Therapy

Documented history and special populations

Live result · computed in your browser

Priority

Adult-only pathway

DQ-001

CPE-003 is validated for adults only; route to the pediatric kidney pathway or provide age.

Detected clinical pattern

Excluded or Data Insufficient

Age is missing or outside the validated adult pathway.

Chronicity: Chronicity confirmed (≥3 months)

Clinical summary

Physician adjudication required.

Recommended next steps

For physician consideration. Urgent review always comes first.

1Monitor blood pressure, serum creatinine and potassium within 2–4 weeks after an ACEi/ARB start or dose increase.

Missing information

Age (required for eGFR and for the adult-only pathway).
UACR (required for the A category, risk assessment and a complete classification).

Why it matters

The result is placed in context so the physician can see what is established, what is provisional and what is missing.

Evidence and rule trace · 2 rules

DQ-001Adult-only validated pathway

Inputs: age missing

excluded_or_data_insufficient

MED-RASI-001RAS inhibitor post-initiation monitoring

Inputs: ACEi/ARB initiated or dose increased

Monitor BP, serum creatinine and potassium within 2–4 weeks

Evidence

R1 · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2024.
R3 · eGFR Equations for Adults: 2021 CKD-EPI creatinine and creatinine-cystatin C race-free equations. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / NIH, 2026.

More kidney cases

CKD-FX-001

Persistent moderately increased albuminuria with preserved GFR

CKD-FX-002

Persistent severely increased albuminuria with mildly decreased GFR

CKD-FX-003

Single reduced eGFR without chronicity

CKD-FX-004

Acute creatinine rise before CKD staging

CKD-FX-005

Isolated suspected G3a requiring cystatin C confirmation support

CKD-FX-006

Combined eGFR reclassification support

All kidney cases

Try Biod in your practice

The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.

Start Free for 3 Months Send us a message